CryoPort Launches Advanced Condition Monitoring Solutions for Life Sciences with MVE Technologies
- CryoPort launches integrated Condition Monitoring Solutions for MVE dewars, enhancing monitoring of critical life science materials.
- The CryoBeacon and SmartTag enable real-time monitoring and temperature logging for ultra-cold storage conditions.
- CryoPort emphasizes regulatory compliance and strategic growth, transitioning towards a subscription-based revenue model for connected solutions.
CryoPort Unveils Cutting-Edge Condition Monitoring Solutions for Life Sciences
CryoPort, Inc. announces the launch of MVE Biological Solutions' integrated Condition Monitoring Solutions, specifically designed for the MVE SC 4/2 V and 4/3 V series dewars. This innovation, powered by Tec4Med, enhances the monitoring capabilities for critical life science materials, ensuring their safe storage and transport. The new solutions integrate advanced technologies such as SmartTagTM and CryoBeaconTM, which are embedded in the lids of the dewars. These devices facilitate centralized monitoring, a crucial aspect in the life sciences industry where the integrity of biological samples is paramount.
The CryoBeacon, a Bluetooth Low Energy (BLE) 5.0 device, has the capability to log internal temperatures as low as –200°C, making it a vital tool for managing ultra-cold storage conditions. Alongside the CryoBeacon, the SmartTag offers real-time monitoring through LTE connectivity and boasts an impressive battery life of up to 120 days. This combination of technologies provides users with enhanced visibility and control over their sensitive materials, which is increasingly vital in a landscape where the efficacy of biological samples can directly impact research outcomes and product development timelines.
MVE President and CEO Mike Duich underscores the significance of these developments, stating that they empower customers to manage their sensitive materials more effectively, ultimately improving operational efficiency. Moreover, Cryoport's Chairman & CEO Jerrell Shelton notes that the introduction of these monitoring devices aligns with the company’s strategic vision to transition towards a subscription-based revenue model. This not only solidifies MVE’s position as a market leader but also sets the stage for further advancements in connected monitoring solutions, ensuring CryoPort remains at the forefront of supply chain innovations in the life sciences sector.
In addition to the innovative monitoring solutions, CryoPort continues to emphasize the importance of compliance with regulatory standards, as evidenced by the MVECloudTM platform’s adherence to FDA 21 CFR Part 11 and GAMP 5. This commitment to regulatory compliance reassures customers of the reliability and security of their data management practices.
As CryoPort sets its sights on the future, the integration of these advanced monitoring technologies not only enhances the management of biological assets but also positions the company for continued growth and innovation within the competitive landscape of life sciences supply chain solutions.
